Analyst Ratings for Ligand Pharma (LGND)
LGND Rating Summary
LGND Price Target Summary
- Highest: $397.00 (Citi)
- Lowest: $289.00 (H.C. Wainwright)
- Average: $342.50
* Over Last 12-Mos
Overall Rating:
BUY
Rating Trend:
=
Avg. $ Target:
$342.50 (+15.9%)
* Over Last 12-Mos
Rating Score: 7.1 / 10
Percentile Rank: 75%
Rating Score: 7.1 / 10
Percentile Rank: 75%
| Date | Firm | Analyst | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 9/25/2026 | Barclays | Glen Santangelo | New Coverage | Overweight (N/A) |
345.00 (N/A) |
298.41 (295.54) |
-0.96% | Details |
| 8/14/2026 | Leerink | David Risinger | New Coverage | Outperform (N/A) |
330.00 (N/A) |
288.82 (295.54) |
2.33% | Details |
 |
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
